Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.

Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B.

Diabetes Obes Metab. 2008 Jun;10(6):506-13. doi: 10.1111/j.1463-1326.2007.00742.x. Epub 2008 Feb 18.

PMID:
18284437
2.

Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.

Freeman-Cook KD, Reiter LA, Noe MC, Antipas AS, Danley DE, Datta K, Downs JT, Eisenbeis S, Eskra JD, Garmene DJ, Greer EM, Griffiths RJ, Guzman R, Hardink JR, Janat F, Jones CS, Martinelli GJ, Mitchell PG, Laird ER, Liras JL, Lopresti-Morrow LL, Pandit J, Reilly UD, Robertson D, Vaughn-Bowser ML, Wolf-Gouviea LA, Yocum SA.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34. Epub 2007 Sep 29.

PMID:
17935984
3.

Potent, selective pyrimidinetrione-based inhibitors of MMP-13.

Reiter LA, Freeman-Cook KD, Jones CS, Martinelli GJ, Antipas AS, Berliner MA, Datta K, Downs JT, Eskra JD, Forman MD, Greer EM, Guzman R, Hardink JR, Janat F, Keene NF, Laird ER, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robertson D, Sperger D, Vaughn-Bowser ML, Waller DM, Yocum SA.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5822-6. Epub 2006 Aug 30.

PMID:
16942871
4.

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.

Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SP, Danley DE, Downs JT, Elliott NC, Eskra JD, Griffiths RJ, Hardink JR, Haugeto AI, Jones CS, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robinson RP, Subramanyam C, Vaughn-Bowser ML, Yocum SA.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1807-10.

PMID:
15780611
5.

Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages.

Trebino CE, Eskra JD, Wachtmann TS, Perez JR, Carty TJ, Audoly LP.

J Biol Chem. 2005 Apr 29;280(17):16579-85. Epub 2005 Feb 18.

6.

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3389-95.

PMID:
15177439
7.

Inhibition of IL-1beta-dependent prostaglandin E2 release by antisense microsomal prostaglandin E synthase 1 oligonucleotides in A549 cells.

Sweeney FJ, Wachtmann TS, Eskra JD, Verdries KA, Lambalot RH, Carty TJ, Perez JR, Audoly LP.

Mol Cell Endocrinol. 2003 Jul 31;205(1-2):151-7.

PMID:
12890577
8.

Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.

Reiter LA, Mitchell PG, Martinelli GJ, Lopresti-Morrow LL, Yocum SA, Eskra JD.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2331-6.

PMID:
12824028
9.

Cartilage damage after intraarticular exposure to collagenase 3.

Otterness IG, Bliven ML, Eskra JD, te Koppele JM, Stukenbrok HA, Milici AJ.

Osteoarthritis Cartilage. 2000 Sep;8(5):366-73.

10.

Effects of nalidixic acid on hamster knee cartilage morphology and synovial fluid composition.

Burkhardt JE, Eskra JD, Clemo FA, Otterness IG.

Toxicol Pathol. 1999 Jul-Aug;27(4):421-6.

PMID:
10485822
11.

Exercise protects against articular cartilage degeneration in the hamster.

Otterness IG, Eskra JD, Bliven ML, Shay AK, Pelletier JP, Milici AJ.

Arthritis Rheum. 1998 Nov;41(11):2068-76.

PMID:
9811063
12.

Limitation of activity in an acute model of arthritis: effect of drug treatment.

Bliven ML, Eskra JD, Otterness IG.

Inflamm Res. 1997 Dec;46(12):491-5.

PMID:
9459079
14.

Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.

Carty TJ, Sweeney FJ, Griffiths RJ, Eskra JD, Ernest MJ, Pillar JS, Cheng JD, Loose LD, Joseph PA, Pazoles PP, Moore PF, Nagahisa A, Murase S, Kadin SB.

Inflamm Res. 1997 May;46(5):168-79.

PMID:
9197987
15.

Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice.

Griffiths RJ, Smith MA, Roach ML, Stock JL, Stam EJ, Milici AJ, Scampoli DN, Eskra JD, Byrum RS, Koller BH, McNeish JD.

J Exp Med. 1997 Mar 17;185(6):1123-9.

16.

The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.

Cheng JB, Watson JW, Pazoles CJ, Eskra JD, Griffiths RJ, Cohan VL, Turner CR, Showell HJ, Pettipher ER.

J Pharmacol Exp Ther. 1997 Feb;280(2):621-6.

PMID:
9023272
17.

Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties.

Moore PF, Larson DL, Otterness IG, Weissman A, Kadin SB, Sweeney FJ, Eskra JD, Nagahisa A, Sakakibara M, Carty TJ.

Inflamm Res. 1996 Feb;45(2):54-61.

PMID:
8907585
18.

Products of arachidonic acid metabolism and the effects of cyclooxygenase inhibition on ongoing cutaneous allergic reactions in human beings.

Atkins PC, Zweiman B, Littman B, Presti C, von Allmen C, Moskovitz A, Eskra JD.

J Allergy Clin Immunol. 1995 Mar;95(3):742-7.

PMID:
7897158
19.

Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans.

O'Connor BJ, Uden S, Carty TJ, Eskra JD, Barnes PJ, Chung KF.

Am J Respir Crit Care Med. 1994 Jul;150(1):35-40.

PMID:
8025768
20.

Role of prostaglandins in the behavioral changes induced by murine interleukin 1 alpha in the rat.

Otterness IG, Golden HW, Seymour PA, Eskra JD, Daumy GO.

Cytokine. 1991 Jul;3(4):333-8.

PMID:
1873481
21.

Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis.

Blackburn WD Jr, Heck LW, Loose LD, Eskra JD, Carty TJ.

Arthritis Rheum. 1991 Feb;34(2):204-10.

PMID:
1847289
22.

The pharmacologic regulation of interleukin-1 production: the role of prostaglandins.

Otterness IG, Bliven ML, Eskra JD, Reinke M, Hanson DC.

Cell Immunol. 1988 Jul;114(2):385-97.

PMID:
2968844
23.

Spectrophotometric monitoring of lipoxygenase and cyclooxygenase pathway activity using ionophore stimulated whole blood.

Sweeney FJ, Eskra JD, Ernest MJ, Carty TJ.

Agents Actions. 1987 Aug;21(3-4):393-6.

PMID:
3120516
25.

Development of a system for evaluating 5-lipoxygenase inhibitors using human whole blood.

Sweeney FJ, Eskra JD, Carty TJ.

Prostaglandins Leukot Med. 1987 Jun;28(1):73-93.

PMID:
3039537
26.
27.

Solid-phase extraction and high-performance liquid chromatography analysis of lipoxygenase pathway products.

Eskra JD, Pereira MJ, Ernest MJ.

Anal Biochem. 1986 Apr;154(1):332-7.

PMID:
3010774
28.

Preparation of [3H]-12-L-hydroxyeicosatetraenoic acid and its use in radioimmunoassay.

Eskra JD, Levine L, Carty TJ.

Prostaglandins Med. 1980 Sep;5(3):201-7.

PMID:
6774356
29.

Piroxicam, a potent inhibitor of prostaglandin production in cell culture. Structure-activity study.

Carty TJ, Eskra JD, Lombardino JG, Hoffman WW.

Prostaglandins. 1980 Jan;19(1):51-9.

PMID:
7384538

Supplemental Content

Loading ...
Support Center